ReviewJournal of bone and mineral metabolism2010
Targeting the bone microenvironment in multiple myeloma.
Review in Journal of bone and mineral metabolism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma.Clinical and experimental medicine · 2023Article
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity.Cancer research · 2021Article
- Pathophysiological role of calcium channels and transporters in the multiple myeloma.Cell communication and signaling : CCS · 2021Review
- Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease.Current osteoporosis reports · 2021Review
- Management of Myeloma Bone Lesions.International journal of molecular sciences · 2021Review
- The Emerging Role of Osteocytes in Cancer in Bone.JBMR plus · 2019Review
- TRPV2-induced CaCell communication and signaling : CCS · 2018Article
- Bone-targeted agents in multiple myeloma.Hematology reports · 2018Article
- Article
- Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.Journal of leukocyte biology · 2017Review
- Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression.Haematologica · 2017Article
- Multiple Myeloma Cells Express Key Immunoregulatory Cytokines and Modulate the Monocyte Migratory Response.Frontiers in medicine · 2017Article
- A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.Oncotarget · 2016Article
- Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.Cancer research · 2016Article
- Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.Journal of molecular medicine (Berlin, Germany) · 2016Review
- Well plate-based perfusion culture device for tissue and tumor microenvironment replication.Lab on a chip · 2015Article
- Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts.PloS one · 2015Article
- Role of osteocytes in multiple myeloma bone disease.Current opinion in supportive and palliative care · 2014Review
- The genetic architecture of multiple myeloma.Advances in hematology · 2014Review
- Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines.Journal of hematology & oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a plasma cell malignancy characterized by the frequent development of osteolytic lesions, osteopenia, pathological fractures, and/or severe bone pain. In the past few years several potential factors involved in this process have been identified and, with the increased knowledge of the signaling pathways involved in the regulation of normal osteoblast and osteoclast function, have provided us with a better understanding of the contributions of the marrow microenvironment to MM bone disease. These studies have identified several potential novel targets for treating MM bone disease in addition to the current standard treatment of bisphosphonates. In this article, we discuss several potential targets for treating MM bone disease as well as novel therapies that are in clinical trials for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.